Description:
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Title
- Brief Title: Study of SRF388 in Patients With Advanced Solid Tumors
- Official Title: A Phase 1/1b Study of SRF388 in Patients With Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
SRF388-101
- SECONDARY ID:
KNC16
- NCT ID:
NCT04374877
Conditions
- Advanced Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
Interventions
Drug | Synonyms | Arms |
---|
SRF388 | | Part A Monotherapy Expansion |
Pembrolizumab | Keytruda® | Part C SRF388 in Combination with Pembrolizumab |
Purpose
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Detailed Description
This is a Phase 1/1b, open-label, first-in-human (FIH), dose-escalation and expansion study
of SRF388, a monoclonal antibody targeting IL-27, as a monotherapy and in combination in
patients with solid tumors that will be conducted in 3 parts:
- Part A: SRF388 monotherapy dose-escalation portion of the study will evaluate the
safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as
monotherapy in patients with advanced solid tumors.
- Part B: SRF388 monotherapy expansion cohorts will evaluate the safety, efficacy,
tolerability, PK, and pharmacodynamics of SRF388 monotherapy in patients with advanced
or metastatic ccRCC (any clear cell component in the histologic definition) and advanced
or metastatic HCC in indication specific cohorts.
- Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in
combination with pembrolizumab in patients with advanced RCC or HCC.
Trial Arms
Name | Type | Description | Interventions |
---|
Part A Monotherapy Expansion | Experimental | The Part A monotherapy dose escalation portion of the study will evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of SRF388 as monotherapy in up to 42 patients with advanced solid tumors. | |
Part B Indication-specific SRF388 Monotherapy Expansion | Experimental | Part B monotherapy expansion will evaluate the safety, tolerability, PK, pharmacodynamics, and efficacy of SRF388 monotherapy at the recommended phase 2 dose (RP2D) in up to 40 patients with ccRCC (any clear cell component in the histologic definition) and up to 40 patients with HCC. | |
Part C SRF388 in Combination with Pembrolizumab | Experimental | Part C will evaluate the safety, preliminary efficacy, tolerability, and PK of SRF388 in combination with pembrolizumab in patients with advanced RCC or HCC. | |
Eligibility Criteria
Part A and Part B Abbreviated Inclusion Criteria:
- ≥ 18 years of age
- Locally advanced or metastatic (Stage IV) solid tumor that has progressed during or
after standard therapy, and for whom no available therapies are appropriate (based on
investigator judgment)
- Patients in Part B with advance or metastatic ccRCC or HCC must have at least 1
measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Patients with HCC in Part B must have at least 1 measurable target lesion according to
modified RECIST (mRECIST)
- Patients with HCC must have unresectable disease, Barcelona Clinic Liver Cancer
(BCLC1) Stage B (not eligible for transcatheter arterial chemoembolization [TACE]) or
Stage C
- For patients in Part B with ccRCC, demonstrated progressive disease (PD) during or
after the most recent treatment regimen. Prior treatment history must include
progression during or after treatment with regimen(s) that have included a vascular
endothelial growth growth factor (VEGF)-targeted agent and an immune checkpoint
inhibitor. Patients who did not progress on but discontinued the VEGF-targeted agent
for toxicity or intolerability are permitted.
- For patients in Part B with HCC, demonstrated PD during or after the most recent
treatment regimen. Prior treatment history must include progression during or after
treatment with a VEGF-targeted agent. Patients who did not progress on but
discontinued the VEGF-targeted agent for toxicity or intolerability are permitted.
- For Part B patients in the tumor biopsy subsets only, must have tumor tissue that is
accessible for pretreatment and on-treatment tumor biopsy in the opinion of the
Investigator and be willing to undergo pretreatment and on-treatment biopsies per
protocol
- Serum creatinine clearance ≥ 30 mL/min per Cockcroft-Gault formula or serum creatinine
≤ 2.0 x the upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN if elevated because of Gilbert's syndrome and ≤
2 x ULN for patients with HCC or patients with known liver metastases)
- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) < 2.5 x
ULN (< 5 x ULN if liver metastasis or for patients with HCC)
- For patients with HCC, Child-Pugh class A or B7 with a serum albumin ≥ 2.8 g/dL (≥ 28
g/L)
- Adequate hematologic function, defined as absolute neutrophil count (ANC) ≥ 1.0 x
109/L, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100 x 109/L. For patients with HCC,
platelet count ≥ 75 x 109/L without transfusion
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Part C Abbreviated Inclusion Criteria:
- Advanced RCC of any histology or advanced HCC previously treated with at least one
systemic anticancer therapy
- Patients with HCC must have unresectable disease, Barcelona Clinic Liver Cancer (BCLC)
Stage B (not eligible for transcatheter arterial chemoembolization) or Stage C
- At least 1 measurable lesion per RECIST 1.1
- Patients with HCC must have at least 1 measurable target lesion according to modified
RECIST (mRECIST)
- ANC ≥1000/µL (1.0 x 109/L)
- Platelets ≥100 000/µL (≥ 100 x 109/L)
- Hemoglobin for participants with RCC: ≥9.0 g/dL1; for participants with HCC: ≥8.5
g/dL1
- Creatinine OR measured or calculated creatinine clearance (GFR can also be used in
place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with creatinine
levels >1.5 × institutional ULN
- Total bilirubin ≤1.5 × ULN OR direct bilirubin ≤ULN for participants with total
bilirubin levels >1.5 × ULN
- AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)
- International normalized ratio (INR) OR prothrombin time (PT) Activated partial
thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant
therapy as long as PT or aPTT is within therapeutic range of intended use of
anticoagulants
- For patients with HCC, Child-Pugh class A or B7 with a serum albumin ≥ 2.8 g/dL (≥ 28
g/L)
- Willingness of male and female patients who are not surgically sterile or
postmenopausal to use medically acceptable methods of birth control for the duration
of the study drug period (or beginning 14 days before the initiation of pembrolizumab
for oral contraception), including 75 days after the last dose of SRF388 or 120 days
after the last dose of pembrolizumab; male patients must refrain from donating sperm
during this period. Sexually active men, and women using oral contraceptive pills,
should also use barrier contraception with spermicide. Azoospermic male patients and
WCBP who are continuously not heterosexually active are exempt from contraceptive
requirements. However, female patients must still undergo pregnancy testing as
described in this section.
Part C Abbreviated Inclusion Criteria Specific to Patients with RCC or HCC from Part A or
Part B:
- Progressed on SRF388 by RECIST 1.1
- Did not experience prior Grade ≥ 3 toxicity related to SRF388
- Willingness to undergo pretreatment core or excisional biopsy if deemed safe and tumor
is accessible, in the opinion of the Investigator
- Has received no systemic anticancer therapies between SRF388 doses
Part A and Part B Abbreviated Exclusion Criteria:
- Previously received an anti-IL-27 antibody or anti-IL-27 targeted therapy
- For patients in Part B with renal cell carcinoma (RCC), non-clear cell RCC histology
- For patients with HCC, fibrolamellar or mixed hepatocellular cholangiocarcinoma
- History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody
therapy or any excipient in the study drugs
- Major surgery within 4 weeks prior to Screening
- Unstable or severe uncontrolled medical condition (eg, unstable cardiac function,
unstable pulmonary condition including pneumonitis and/or interstitial lung disease,
uncontrolled diabetes) or any important medical illness or abnormal laboratory finding
that would, in the Investigator's judgment, increase the risk to the patient
associated with his or her participation in the study
Part C Abbreviated Exclusion Criteria:
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study drug
- Previously received an anti-IL 27 antibody or anti-IL 27 targeted therapy (exception
to patients who received SRF388 in Part A or Part B)
- No prior systemic therapy for unresectable or metastatic disease
- Received > 5 prior systemic regimens for unresectible or metastatic disease (prior
PD-(L)1 inhibitors are allowed if the patient did not discontinue therapy due to ≥
Grade 3 drug-related toxicity)
- For patients with HCC, fibrolamellar histology or mixed hepatocellular
cholangiocarcinoma
- For patients with HCC, moderate or severe ascites
- For patients with HCC, inability to undergo disease evaluation with triphasic computed
tomography or magnetic resonance imaging because of contrast allergy or other
contraindication
- For patients with HCC, imaging findings consistent with ≥ 50% liver occupation by HCC
tumors
- History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody
therapy or any excipient in the study drugs
- Surgeries that required general anesthesia must be completed at least 2 weeks before
first study drug administration
- Prior autologous stem cell transplant ≤ 3 months before the first dose
- Prior allogeneic hematopoietic cell transplant within 6 months of the first dose or
with a history of or current clinical Graft-Versus-Host Disease
- Has had an allogenic tissue/solid organ transplant
- Other unstable or severe uncontrolled medical condition (eg, unstable cardiac
function, unstable pulmonary condition, uncontrolled diabetes) or any important
medical illness or abnormal laboratory finding that would, in the Investigator's
judgment, increase the risk to the patient associated with his or her participation in
the study
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | [Part A] Dose Limiting Toxicity (DLT) |
Time Frame: | Assessed during first 28 days of treatment |
Safety Issue: | |
Description: | Evaluation of DLT of SRF388 as a monotherapy. |
Secondary Outcome Measures
Measure: | [Part A, Part B] Safety Analysis: Summary of adverse events (AEs) and based on treatment-emergent AEs (TEAEs) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | Safety and tolerability of SRF388 will be assessed by summarizing adverse events (AEs) and will be based on treatment-emergent AEs (TEAEs). |
Measure: | [Part A, Part B, Part C] Pharmacokinetics (PK) of SRF388 |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | Serum concentrations of SRF388 will be collected and analyzed to evaluate the PK of SRF388. |
Measure: | [Part A, Part B] Pharmacodynamics of SRF388 (pSTAT levels) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | Pharmacodynamics of SRF388 will be evaluated in immune cell subsets via whole blood. |
Measure: | [Part A, Part C] Objective response rate (ORR) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | ORR will be estimated by the percentage of patients achieving a best overall response of CR or PR per RECIST v1.1 and iRECIST. |
Measure: | [Part A, Part B, Part C] Duration of response (DoR) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | DoR is defined as the time from the first documented response (CR or PR) to documented disease progression as determined by applicable disease criteria, or documented death due to any cause, whichever occurs first. |
Measure: | [Part A, Part B, Part C] Disease control rate (DCR) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | DCR is defined as the percentage of patients with CR, partial PR, or stable disease lasting a minimum of 12 weeks. |
Measure: | [Part A, Part B, Part C] Progression-free survival (PFS) |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | PFS is defined as the time from the first treatment on study with study drug to documented disease progression as determined by applicable disease criteria or death. |
Measure: | [Part C] Serum concentration of EBI3 |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | Serum will be collected to assess EBI3 correlation with outcomes. |
Measure: | [Part C] Anti-drug Antibodies (ADAs) to SRF388 |
Time Frame: | Up to 24 months |
Safety Issue: | |
Description: | Serum will be collected and assessed for the development of ADAs to SRF388. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Surface Oncology |
Trial Keywords
- metastatic solid tumors
- advanced solid tumors
- Phase 1
- SRF388
- IL-27
- safety
- efficacy
- immunotherapy
- cancer
- immuno-oncology
- kidney cancer
- renal cell carcinoma
- liver cancer
- hepatocellular carcinoma
Last Updated
August 24, 2021